Serious adverse events · people without inhibitors
Summary of findings table ‐ Emicizumab 1.5 mg/kg once weekly showed no clear difference in serious adverse events compared with emicizumab 3.0 mg/kg every 2 weeks (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people without inhibitors
1 finding from 1 review
Annualized joint Bleeding Rate (AjBR) · people without inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people without inhibitors
1 finding from 1 review
Proportion with zero bleeds · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people without inhibitors
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events ‐ Serious adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in adverse events ‐ Serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
QoL · people with inhibitors
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Serious adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Annualized Bleeding Rate (ABR) ‐ All treated bleeds · people with inhibitors
1 finding from 1 review
Annualized spontaneous Bleeding Rate (AsBR) · people with inhibitors
1 finding from 1 review
Cases of cholera ( · healthy children and adults; high risk population
1 finding from 1 review
Cases of cholera ( · healthy children and adults; high risk population
3 findings from 1 review
no estimate extracted
1 study · 54519 participants
High
no estimate extracted
2 studies · 168540 participants
Moderate
no estimate extracted
2 studies · 241631 participants
High
Cases of cholera ( · healthy children and adults, male and female; high risk population
2 findings from 1 review
Cases of severe dehydrating cholera ( · healthy children and adults, male and female; high risk population
2 findings from 1 review
Proportion of participants developing a cold Duration of · adults and children without colds
1 finding from 1 review
Proportion with improved global symptom severity Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review
Risk of adverse events, including those that may be due to zinc supplements Duration of · adults and children with colds and/or upper respiratory infections
1 finding from 1 review